全文获取类型
收费全文 | 828篇 |
免费 | 50篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 37篇 |
妇产科学 | 18篇 |
基础医学 | 122篇 |
口腔科学 | 5篇 |
临床医学 | 58篇 |
内科学 | 170篇 |
皮肤病学 | 8篇 |
神经病学 | 25篇 |
特种医学 | 11篇 |
外科学 | 138篇 |
综合类 | 35篇 |
预防医学 | 53篇 |
眼科学 | 54篇 |
药学 | 43篇 |
中国医学 | 6篇 |
肿瘤学 | 92篇 |
出版年
2023年 | 4篇 |
2022年 | 21篇 |
2021年 | 43篇 |
2020年 | 13篇 |
2019年 | 15篇 |
2018年 | 34篇 |
2017年 | 25篇 |
2016年 | 29篇 |
2015年 | 31篇 |
2014年 | 32篇 |
2013年 | 47篇 |
2012年 | 54篇 |
2011年 | 47篇 |
2010年 | 34篇 |
2009年 | 32篇 |
2008年 | 38篇 |
2007年 | 32篇 |
2006年 | 40篇 |
2005年 | 36篇 |
2004年 | 44篇 |
2003年 | 34篇 |
2002年 | 28篇 |
2001年 | 9篇 |
2000年 | 11篇 |
1999年 | 14篇 |
1998年 | 7篇 |
1997年 | 4篇 |
1996年 | 4篇 |
1994年 | 4篇 |
1992年 | 3篇 |
1991年 | 5篇 |
1990年 | 4篇 |
1989年 | 4篇 |
1988年 | 6篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 5篇 |
1980年 | 3篇 |
1979年 | 8篇 |
1973年 | 4篇 |
1972年 | 4篇 |
1971年 | 6篇 |
1970年 | 10篇 |
1969年 | 6篇 |
1968年 | 6篇 |
1967年 | 8篇 |
1966年 | 2篇 |
1965年 | 2篇 |
排序方式: 共有878条查询结果,搜索用时 453 毫秒
31.
Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. 总被引:4,自引:2,他引:4
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
32.
Complement and cell mediated cytotoxicity by antiendothelial cell antibodies in Takayasu's arteritis
OBJECTIVE: To study complement and cell mediated cytotoxicity by antiendothelial cell antibodies (AECA) in Takayasu's arteritis (TA). METHODS: Complement dependent cytotoxicity (CDC) and antibody dependent cellular cytotoxicity (ADCC) of AECA positive/negative TA sera were investigated by colorimetric MTT and 51Cr release assays, respectively, using human umbilical vein endothelial cells (HUVEC) as targets. RESULTS: Seven of 12 (58%) sera positive for IgG and/or IgM AECA exhibited CDC in comparison to none of the 13 AECA negative sera (p = 0.0052). The median value of CDC of the AECA positive group was 14% (range 13-21%) and that of the AECA negative group was 1% (p = 0.0012). Interleukin 1beta (10 U/ml) treatment of HUVEC resulted in enhancement in CDC of 6 of the 7 AECA positive cytotoxic sera, the median enhancement being 17% (range 7-29%). Tumor necrosis factor-alpha (100 U/ml) treatment of the targets resulted in a median enhancement by 36% (range 25-55%) in the CDC of 3 of these 7 sera. No sera exhibited ADCC at any of the effector:target ratios tested (10:1 to 100:1). CONCLUSION: AECA in TA mediate CDC against endothelial cells and may have a pathogenic role in the perpetuation of vascular damage in this disease. 相似文献
33.
Tripathy SP Kulkarni SS Jadhav SD Agnihotri KD Jere AJ Kurle SN Bhattacharya SK Singh K Tripathy SP Paranjape RS 《AIDS research and human retroviruses》2005,21(2):152-157
The predominant HIV-1 strain circulating in India is subtype C. However, subtype A and B strains of HIV-1 have also been reported in India. In 1999, the first A/C recombinant strain was reported from Pune in India. Intravenous drug users (IVDUs) from the northeastern region of India have a high HIV-1 seroprevalence. Studies carried out in intravenous drug users in the northeastern region of India have shown that HIV-1 subtype C is the predominant strain infecting IVDUs. Fourteen blood samples were collected from HIV-1-infected individuals from the northeastern region of India and screened by env and gag heteroduplex mobility assays (HMA). Where the env and gag HMA results from a sample yielded different subtypes, sequencing of env and gag PCR products was carried out to confirm the presence of HIV-1 recombinants. Of the 14 samples subtyped, nine samples belonged HIV-1 subtype C (gag C/env C), one to HIV-1 subtype B (gag B/env B), and the remaining were B/C recombinants (gag C/env B). This is the first report of HIV-1 B/C recombinants from India. 相似文献
34.
Dewi Megawati Ita M. Nainggolan Maria Swastika Susi Susanah Johanes C. Mose Alida R. Harahap 《Hemoglobin》2014,38(2):149-151
We report a novel mutation at codon 24 of the α2-globin gene (HBA2: c.75T?>?A) found in a Sundanese family. This novel mutation was detected during prenatal diagnosis. The couple already had a 7-year-old boy who exhibited clinically severe α-thalassemia intermedia (α-TI), and he was found to be a compound heterozygote for the novel mutation at codon 24 and the previously described Hb Adana (HBA2: c.179G?>?A) at codon 59 of the α2-globin gene. The father was a carrier of the novel point mutation and showed normal hemoglobin (Hb) and a low mean corpuscular volume (MCV) and mean corpuscular Hb (MCH) value. 相似文献
35.
36.
Evidence for a potent antiinflammatory effect of rosiglitazone 总被引:35,自引:0,他引:35
Mohanty P Aljada A Ghanim H Hofmeyer D Tripathy D Syed T Al-Haddad W Dhindsa S Dandona P 《The Journal of clinical endocrinology and metabolism》2004,89(6):2728-2735
We have recently demonstrated a potent antiinflammatory effect of troglitazone, an agonist of peroxisome proliferator-activated receptor gamma (PPARgamma) and a partial agonist of PPARalpha in both the nondiabetic obese and diabetic obese subjects. We have now investigated the antiinflammatory actions of rosiglitazone, a selective PPARgamma agonist. Eleven nondiabetic obese subjects and 11 obese diabetic subjects were each given 4 mg of rosiglitazone daily for a period of 6 wk. Fasting blood samples were obtained at 0, 1, 2, 4, 6, and 12 wk (6 wk after the cessation of rosiglitazone). Eight obese subjects and five obese diabetic subjects were also included in the study as control groups. Fasting blood samples were obtained from the control groups at 0, 1, 2, 4, and 6 wk only. Nuclear factor kappaB (NFkappaB)-binding activity in mononuclear cells, plasma monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, soluble intercellular adhesion molecule-1, C-reactive protein (CRP), and serum amyloid A (SAA) were measured. Blood glucose concentration changed significantly at 6 wk only in the obese diabetic subjects after rosiglitazone treatment for 6 wk, whereas insulin concentration decreased significantly at 6 wk in both groups. NFkappaB-binding activity in mononuclear cell nuclear extract fell in both obese and obese diabetic subjects (P < 0.02). Rosiglitazone treatment resulted in a reduction in plasma MCP-1 and CRP in both groups (P < 0.05). Plasma TNF-alpha and SAA concentrations were inhibited significantly in the obese group (P < 0.05) but not in the obese diabetic subjects. NFkappaB-binding activity and plasma MCP-1, CRP, SAA, and TNF-alpha did not change in the obese and obese diabetic control groups. We conclude that rosiglitazone, a selective PPARgamma agonist, exerts an antiinflammatory effect at the cellular and molecular level, and in plasma. These observations may have implications for atherogenesis in the long term in subjects treated with rosiglitazone and possibly other thiazolidinediones. 相似文献
37.
Arnon S Shiff Y Litmanovitz I Regev RH Bauer S Shainkin-Kestenbaum R Bental Y Dolfin T 《American journal of perinatology》2007,24(2):95-100
The purpose of this study was to examine the efficacy and safety of early nonionic iron supplementation in preterm infants. Infants with gestational age < or = 32 weeks who were fed enriched human milk were assigned concurrently to receive 5 mg/kg/d enteral iron polymaltose complex (IPC) at 2 or 4 weeks of age. The levels of hemoglobin, reticulocytes, serum iron, ferritin, and soluble transferrin receptor were recorded at 2, 4, and 8 weeks of age. The incidence of morbidities associated with prematurity and the need for red blood cell transfusions (RBCTs) were recorded. The 2-week group (n = 32) had a better iron status than the 4-week group (n = 36) at 4 weeks and at 8 weeks of age. The incidence of morbidities associated with prematurity was not different among the groups ( P = 0.26). RBCT was required in one infants of the 2-week group and in 10 infants in the 4-week group ( P = 0.045). The number needed to treat to prevent one RBCT was five. Supplementation of 5 mg/kg/d enteral IPC to preterm infants fed enriched human milk as early as 2 weeks of age was more beneficial to iron status than at 4 weeks of age, and was associated with decreased need for RBCTs and no increase in the incidence of morbidities associated with prematurity. 相似文献
38.
Satyaswarup Tripathy Devi Prasad Mohapatra Ranjit Kumar Sahu Subair Mohsina Ramesh Kumar Sharma Subhendu Khan Sharda Renu Chandra Kunwari Singh Suraj R. Nair Shijina Koliath Imran Pathan 《Indian Journal of Plastic Surgery》2022,55(1):45
Introduction The study was carried out to quantify the changes induced by the pandemic in plastic surgery practice and training and to study the impact of the webinars on plastic surgery education from a residents’ perspective. Methods In this multicentric study, the number and type of surgeries, cause of injuries, and their regional variation during the coronavirus disease 2019 (COVID-19) period (February–September 2020) were compared with pre–COVID-19 time. An online survey on the impact of webinars was conducted for plastic surgery trainees across the country. Results There was a significant reduction in total number of surgeries ( p = 0.003). The procedures for hand ( p = 0.156), faciomaxillary injuries ( p = 0.25), and replantations ( p = 0.46) were comparable; there was a significant reduction in combined orthopedic-plastic-surgical procedures ( p = 0.009) during the pandemic. There was a significant reduction in road accidents ( p = 0.007) and suicidal injuries ( p = 0.002) and increase in assault ( p = 0.03) and domestic accidents ( p = 0.01) during the COVID-19 period. A usefulness score of >8 was given for the webinars by 68.7% residents. There was no significant difference in perception of utility when correlated with the academic program at their institutes ( p = 0.109); 92% opined webinars should continue in post-COVID times. Conclusion There was a drastic reduction in number of elective and emergency procedures during the COVID-19 time, negatively affecting resident training program. Majority of residents felt that webinars could prove a useful adjunct to training in formal training program in post-COVID-19 scenario. 相似文献
39.
Julie Wecsler MD Young Ju Jeong MD PhD Akshara S. Raghavendra MD MS Wendy J. Mack PhD Debasish Tripathy MD Mary W. Yamashita MD Pulin A. Sheth MD Linda Hovanessian Larsen MD Christy A. Russell MD Heather MacDonald MD Stephen F. Sener MD FACS Julie E. Lang MD FACS 《Journal of surgical oncology》2020,121(4):589-598